EUVIMEDEUVIMED entdecken
Crossref

Bortezomib and Vorinostat Therapy as Maintenance Therapy Post-Autologous Transplant for Non-Hodgkin’s Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen

Leona A Holmberg, David G Maloney, Laura Connelly-Smith

Acta Haematologica · 2024

DOI: 10.1159/000533944 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Haematologica, 2024. Verfasst von Leona A Holmberg und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Vorinostat, Bortezomib, Lymphoma, Non-Hodgkin, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The success of autologous stem cell transplantation (ASCT) for treating non-Hodgkin’s lymphoma (NHL) is limited by its high relapse rates. To reduce the risk of relapse, additional maintenance therapy can be added post-transplant. In a non-transplant setting at the time of initiation of this study, both bortezomib and vorinostat had been studied alone or in combination for some NHL histology and showed some clinical activity. At our center, this combination therapy post-transplant for multiple myeloma showed acceptable toxicity. Therefore, it seemed reasonable to study this combination therapy post-ASCT for NHL.

Methods

NHL patients underwent conditioning for ASCT with rituximab, carmustine, etoposide, cytarabine, melphalan/carmustine, etoposide, cytarabine, melphalan. After recovery from the acute transplant-related toxicity, combination therapy with IV bortezomib and oral vorinostat (BV) was started and was given for a total of 12 (28-day) cycles.

Results

Nineteen patients received BV post-ASCT. The most common toxicities were hematologic, gastrointestinal, metabolic, fatigue, and peripheral neuropathy. With a median follow-up of 10.3 years, 11 patients (58%) are alive without disease progression and 12 patients (63%) are alive.

Conclusions

BV can be given post-ASCT for NHL and produces excellent disease-free and overall survival rates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VorinostatBortezomibLymphoma, Non-HodgkinAntineoplastic Combined Chemotherapy ProtocolsMelphalanTransplantation ConditioningEtoposideCytarabineTransplantation, AutologousHumansMiddle AgedFemaleMaleAgedAdultCarmustineHydroxamic AcidsHematopoietic Stem Cell TransplantationPodophyllotoxinRituximabMaintenance Chemotherapy

Stichwörter der Autor:innen

Autologous stem cell transplantationBortezomibNon-Hodgkin’s diseasePost-transplant therapyVorinostat

Substanzen

VorinostatBortezomibMelphalanEtoposideCytarabineCarmustineHydroxamic AcidsPodophyllotoxinRituximab

Autor:innen und Institutionen

  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Department of Medicine, University of Washington, Seattle, Washington, USA.

Zitieren

APA

Holmberg, L. A., Maloney, D. G., & Connelly-Smith, L. (2024). Bortezomib and Vorinostat Therapy as Maintenance Therapy Post-Autologous Transplant for Non-Hodgkin’s Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen. Acta Haematologica. https://doi.org/10.1159/000533944

Vancouver

Holmberg LA, Maloney DG, Connelly-Smith L. Bortezomib and Vorinostat Therapy as Maintenance Therapy Post-Autologous Transplant for Non-Hodgkin’s Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen. Acta Haematologica. 2024. doi:10.1159/000533944

BibTeX
@article{Holmberg2024,
  author = {Holmberg, Leona A and Maloney, David G and Connelly-Smith, Laura},
  title = {Bortezomib and Vorinostat Therapy as Maintenance Therapy Post-Autologous Transplant for Non-Hodgkin’s Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen},
  journal = {Acta Haematologica},
  year = {2024},
  doi = {10.1159/000533944}
}
Kostenlos starten →